Valbiotis appoints Josep Infesta Valbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development. more ➔
Asceneuron appoints Peter Van Vlasselaer Asceneuron, a company in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as … more ➔
Pharnext announces two appointments Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer. more ➔
Immuno-Oncology experts to join Protagen A... Protagen AG, a precision medicine specialist at the forefront of immuno-profiling, announced today the appointment of Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, … more ➔
Immunocore appoints Bahija Jallal as CEOImmunocore has appointed Bahija Jallal as Chief Executive Officer and Director of the Board. more ➔
Gilead names Daniel ODay CEO Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel ODay Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. ODay … more ➔
Genentech CEO to switch to Roche Pharma William Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019. He will be based in Basel, report to Severin Schwan, Roche Group CEO and become a … more ➔
Forbion appoints Dr. Carlo Incerti as Oper... Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019. more ➔
Merck appoints Jasper Bos as Managing Dire... Merck today announced the appointment of Jasper Bos as the new Managing Director of its strategic corporate venture capital arm M Ventures. more ➔
Bergenbio appoints Alan Barge MD as interi... Bergenbio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, has announced the appointment of Alan … more ➔